Authors


Lance Scott

Latest:

Data Inflection Point

The time is now for pharma to take next steps in tech adoption.


Peter Sturtevant

Latest:

Key Regulatory Deadlines Loom for Drug Dispensers and Wholesalers

The COVID-19 pandemic is currently top of mind among pharma professionals, but stakeholders have other business to attend to – such as the upcoming deadline to meet regulatory requirements of the US FDA’s 2013 Drug Supply Chain Security Act.


Lisa Kerber

Latest:

AI & Lab Data: Enabling Decision-Making in Real Time

Lisa Kerber outlines how the pharma industry can take advantage of combining new clinical data sources such as diagnostics, or lab data, with AI to deliver on the promise of improving outcomes.


Leslie Isenegger

Latest:

Can A New Value Framework Help Ease Friction Over Orphan Drug Prices?

Even on the contentious topic of orphan drug pricing, the last few months have brought hopeful signs that patients, pharmaceutical companies, health insurers, and the academic bodies that counsel them are trying to speak the same language.




Vicki Anastasi

Latest:

mHealth: Changing the Dynamics of the Healthcare Ecosystem

mHealth devices and apps that continuously monitor patient symptoms and help with adherence also are likely to reshape medical practice – and with it the products pharma produce, writes Vicki Anastasi.


Charles Benaiah

Latest:

Talk About Talk

Audio platforms provide new opportunities for pharma.


Kevin Troyanos

Latest:

Why Your Advertising Agency Should Be Your Analytics Partner

Brands should look to their agencies to be a true data-driven business partner, not just a creative partner, writes Kevin Troyanos.


Jayachandra Reddy and Rishit Thakkar

Latest:

Navigating the Untapped NASH Market

A potential rush of treatment options on the horizon for non-alcoholic steatohepatitis will require skillful maneuvering in this likely lucrative but uncharted therapeutic market.




Jackie Ilacqua & Valerie Wriede

Latest:

The Rising Tide of Next Generation Cancer Treatments

The Ipsos Healthcare Oncology Centre of Excellence's Jackie Ilacqua & Valerie Wriede trace the evolution of cancer treatment and drill down into the latest developments currently redefining the landscape, together with those on the horizon.


Mariel Metcalfe

Latest:

NASH: Pointers for Pharma from the Patient Perspective

With the NASH pipeline filling up fast, Mariel Metcalfe looks at what pharma companies need to do to ensure their products do not end up as also-rans in this dynamic new market segment.



Adam Nelson

Latest:

How Pharmas, Payers, and Providers Can Meet the ‘Triple Aim’

Today’s model requires a fourth partner-the systems integrator



Bhaskar Sambasivan

Latest:

Rebooting Life Sciences with Digital

Mastering digital business strategies and tactics will enable life sciences companies to supercharge innovation and speed therapy discovery, patient centric-practices and improved health outcomes, writes Bhaskar Sambasivan.


MilliporeSigma

Latest:

e-Data and the Biopharmaceutical Supply Chain

MilliporeSigma’s Stephen Wing, head of Analytical and Logistical Services, discusses the ways in which digital transformation and data transparency dramatically enhance supply chains, and how manufacturers are using the company’s eMERGE™ platform to improve overall efficiencies.


James Talerico

Latest:

Are We Slaves to Predictability?

The status quo pharma marketing model is still relied upon by the big brands, not because the results are amazing, but because they are predictable. It's time to challenge convention, says James Talerico.


Shelby Buettner

Latest:

When HIPAA Doesn’t Apply

Outlining the common data transactions between life sciences companies and the HIPAA-regulated stakeholders they deal with daily-and steps pharma can take to secure and protect its own data.


Jennifer S. Geetter

Latest:

When HIPAA Doesn’t Apply

Outlining the common data transactions between life sciences companies and the HIPAA-regulated stakeholders they deal with daily-and steps pharma can take to secure and protect its own data.


Brenda L. Gleason

Latest:

How Can We Be Healthcare Leaders Right Now?

Brenda Gleason discusses the current health policy landscape and how future pharmacists can be healthcare leaders during a lecture at University of North Carolina Eshelman School of Pharmacy.


Howard Pezim and Darren Raycroft

Latest:

Resilience in a Sea of Change: Ed Gudaitis, GM – Canada, Allergan

Ed Gudaitis Allergan VP and Country Manager, Canada, explains how embracing disruption is his secret to success.



John Maslowski

Latest:

Developing Drugs for Rare Diseases: Insights for Pharma Execs

This article explores the difficult nature of developing drugs for rare diseases and discusses what a pharmaceutical executive can actively do to help increase success.


Harriet Kozak

Latest:

Medical Marijuana: A Challenge to Traditional Pain Relief?

Medical use of marijuana for a broad range of conditions is expanding rapidly in the US, but the future for this market is still uncertain, writes Harriet Kozak.


Kimberly E. White

Latest:

Engaging in Risk-Sharing Agreements with Providers

Before entering into risk-sharing agreements, manufacturers must understand the challenges and implications, writes Kimberly E. White.


IQVIA

Latest:

Global Real World Data Tour: 2024 Key Insights

Webinar Date/Time: Wednesday, October 9th, 2024 at 11am EDT | 8am PDT | 4pm BST | 5pm CEST


John Sattler

Latest:

Job Hunter Meet Headhunter (aka Executive Recruiter)

John Sattler offers some tips on engaging executive and professional recruiters.